🍪 The GLP Lounge uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsDosing & ProtocolsHas anyone dealt with dose-response curves?

Has anyone dealt with dose-response curves?

sophie_paris Wed, Feb 18, 2026 at 10:03 PM 19 replies 1,156 viewsPage 1 of 4
sophie_paris
Member
212
890
Nov 2024
Paris, FR
Feb 18, 2026 at 10:03 PM#1

Posting this because the summary going around does not say what the paper says, and the difference matters for how people here are using it.

Holding longer is the underrated move. A step that is uncomfortable at week two is frequently comfortable at week six with no change in dose, because the gastric-emptying component tachyphylaxes while the appetite effect persists. Escalating at week two throws that adaptation away.

Where I think it is weakest: the follow-up is short relative to how long people actually take these drugs, so durability is an assumption here rather than a finding.

What I am after is why the interval is four weeks rather than two, and whether a slower ladder gets to the same place. I would rather have one careful answer than five confident ones.

Note on sourcing:
Figures above are from the primary publication rather than the press summary. If a number here disagrees with one you have, post yours and we will work out which of us is reading a secondary source.
30 0SallyK_inj, CryptoCarl, MariaRD and 27 others
Reply Quote Save Share Report
julia.endo
Senior Member
1,890
9,012
Feb 2024
Cincinnati, OH
Feb 18, 2026 at 10:42 PM#2
sophie_paris said:
A step that is uncomfortable at week two is frequently comfortable at week six with no change in dose, because the gastric-emptying component…

sophie_paris has the substance of this right. The condition it depends on is worth stating. The trials generally allowed a step to be held or reduced and then retried, and people who did that mostly arrived at the same place a few weeks later. The end point of the ladder is set by tolerability, not by a schedule, and there is no evidence that reaching the top faster produces a better outcome.

29 24mark_tokyo, hans_munich, jason_sac26 and 26 others
Reply Quote Save Share Report
JennaRN
Senior Member
1,987
8,923
Mar 2024
Colorado
Online
Feb 18, 2026 at 11:21 PM#3
sophie_paris said:
A step that is uncomfortable at week two is frequently comfortable at week six with no change in dose, because the gastric-emptying component…

I disagree that the ladder is purely tolerability. The maintenance and regain data cluster at the top doses, so a ladder abandoned halfway leaves you outside the evidence base for the part that matters most — keeping it off.

Last edited: Feb 19, 2026 at 12:21 AM
28 23BiostatsBrad, PeptideSynthNJ, Dr.KarenChen and 25 others
Reply Quote Save Share Report

Sigma-Aldrich — Research-Grade Standards

Certified reference materials, analytical reagents, and research-grade standards for peptide verification. Trusted by laboratories worldwide.

Shop Reference Standards
JenPlateau
Member
234
890
Nov 2024
Missouri
Feb 19, 2026 at 12:00 AM#4

This one has a reasonably settled answer, so here it is. Four weeks is the pharmacokinetics, not caution. With a one-week half-life you need four to five half-lives to reach steady state, so at two weeks you are dosing on top of a concentration that has not finished rising. Escalating then stacks exposure and you get the side-effect burden of the higher dose before you have seen the benefit of the current one.

Last edited: Feb 19, 2026 at 6:00 AM
27 22FitDadDave, RunnerRach, TrialNerd_Beth and 24 others
Reply Quote Save Share Report
pam_stl
Member
267
1,123
Oct 2024
St. Louis, MO
Feb 19, 2026 at 3:36 AM#5
julia.endo said:
The trials generally allowed a step to be held or reduced and then retried, and people who did that mostly arrived at the same place a few weeks…

Can confirm. Same sequence, different timescale. Nothing to add that would improve it.

Last edited: Feb 19, 2026 at 8:36 AM
26 21RegAffairsDC, BiostatsBrad, PeptideSynthNJ and 23 others
Reply Quote Save Share Report

Similar Threads

Micro-dosing semaglutide — is sub-therapeutic dosing effective?16 replies
Injection technique: subcutaneous depot formation and absorption8 replies
Semaglutide PK modeling — when to time your injection12 replies
Reconstitution calculator — compounded peptide dosing math7 replies
Half-life implications for missed doses — PK-based guidance5 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register